Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

CLICK HERE FOR CME CREDIT

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Erik S.G Stroes, MD, PhD

Erik S.G Stroes, MD, PhD

Professor Department of Vascular Medicine Academic Medical Center Amsterdam, The Netherlands